Resources and Insurance
Safety Information
 

RITUXAN Access Solutions—Connecting You to the Medicine You Need

Regardless of your insurance status, we can help:

  • Find out if your health plan pays for your medicine
  • Guide you through the reimbursement process
  • Connect you with programs that may help you with out-of-pocket costs
  • Give you and your doctor’s office personal help from a member of our support team

Contact RITUXAN Access Solutions

The Genentech BioOncology Co-pay Card

 

At Genentech, we are committed to helping patients access the treatment they need. That's why we offer the Genentech BioOncology Co-pay Card. If you are eligible, this card can help lower the out-of-pocket costs like co-payments, co-insurance or deductibles for your Genentech cancer therapy.

  • Out-of-pocket costs are the part of your treatment that your healthcare plan requires you to pay. Check eligibility

Contact RITUXAN Access Solutions to learn more about the Genentech BioOncology Co-pay Card

Genentech® Access to Care Foundation

The Genentech Access to Care Foundation (GATCF) helps patients who do not have insurance coverage for a Genentech medicine. Qualified patients enrolled in GATCF receive their medicine free of charge.

  • We are committed to helping you get our medicines regardless of your ability to pay
  • If you have no insurance, or your health insurance plan denies you coverage for RITUXAN, you can work with your doctor’s office to apply to GATCF for free medicine

Contact RITUXAN Access Solutions to learn more about the Genentech Access to Care Foundation (GATCF)

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

Next Section Educational Materials

Indications

RITUXAN® (Rituximab) is indicated in combination with fludarabine and cyclophosphamide (FC chemotherapy) for the treatment of patients with:

  • Previously untreated CD20-positive CLL
  • Previously treated CD20-positive CLL

People with serious infections should not receive RITUXAN.

Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in clinical trials of patients with CLL were infusion reactions and low white blood cells, which can increase the risk of infections. Before starting treatment with RITUXAN it is important for you to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide, in PDF format.